Head and neck cancer trials in China
216 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in ChinaUnplanned Hospitalization and Emergency Department Use in Patients With Head and Neck Cancer Receiving Radiotherapy
- Where
- Changsha
- Age
- 18 years and over
- People
- 657
- Run by
- Xiangya Hospital of Central South University
See details and how to joinNCT07929194 - Phase 2Taking peopleTraditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.
- Where
- Chengdu
- Age
- 18 years to 65 years
- People
- 128
- Run by
- West China Hospital
See details and how to joinNCT07339774 - Phase 1Taking peopleA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Where
- Changsha
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Beijing, Guangzhou, Shanghai
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 2Not yet taking people in ChinaBecotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction Immunochemotherapy
- Where
- Guangzhou, Shenzhen
- Age
- 18 years to 70 years
- People
- 22
- Run by
- Sun Yat-sen University
See details and how to joinNCT07915258 - Phase 3Taking peopleJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Where
- Bengbu, Changsha, Chengdu, Dongguan, Fuzhou, Guangzhou, Jinan, Linyi, Liuzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou, Zhuhai
- Age
- 60 years and over
- People
- 500 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT04892173 · EU 2024-520386-31-00 - Phase 1/2Taking peopleA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- Where
- Beijing, Cheng Du Shi, Linyi, Shanghai, Wuhan
- Age
- 18 years and over
- People
- 287 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06385080 · EU 2023-508418-40-00 - Phase 3Taking peopleA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Where
- Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou, Jinan, Kunming, Linyi, Nanjing, Nanning, Shanghai, Wuhan, Xi'an, Yibin
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00 - No phaseTaking peoplePDO Based Drug Sensitive Test in R/M HNSCC
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 100
- Run by
- Huashan Hospital
See details and how to joinNCT06686342 - Phase 2Taking peopleLocally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study
- Where
- Hebei
- Age
- 18 years to 75 years
- People
- 86
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07906587 - Phase 2Taking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Beijing, Changsha, Chengdu, Dongguan, Henan, Hubei, Shanghai, Shenyang, Wuhan, Xi'an, Xinxiang, Xuzhou
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 2Taking peopleSuperoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer
- Where
- Chengdu
- Age
- 18 years to 80 years
- People
- 140
- Run by
- West China Hospital
See details and how to joinNCT07704372 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Chengdu, Guangzhou
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Where
- Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
- Age
- 18 years and over
- People
- 862 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05914116 - Phase 2Taking peopleIparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 26
- Run by
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
See details and how to joinNCT07882888 - Phase 2Taking peopleSYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 110
- Run by
- CSPC Megalith Biopharmaceutical Co.,Ltd.
See details and how to joinNCT07254585 - Phase 1/2Taking peoplePhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Where
- Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
- Age
- 18 years and over
- People
- 233 worldwide
- Run by
- Ensem Therapeutics
See details and how to joinNCT06993844 - Phase 2/3Taking peopleA Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
- Where
- Shanghai
- Age
- 18 years and over
- People
- 362
- Run by
- Taizhou Mabtech Pharmaceutical Co.,Ltd
See details and how to joinNCT07791745 - Phase 3Taking peopleCetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 316
- Run by
- Ji Dongmei
See details and how to joinNCT07509099 - Phase 3Taking peopleA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- Where
- Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongwan, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Huizhou, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Ürümqi, Wuhan, Wuxi, Xiamen, Xi'an, Zhengzhou, Zhuhai
- Age
- 18 years to 130 years
- People
- 1,145 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06129864 - Phase 3Taking peopleNeoadjuvant Immunochemotherapy for LAOSCC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 134
- Run by
- Lai-ping Zhong
See details and how to joinNCT06258811 - No phaseTaking peopleNeck Observation or Elective Neck Dissection in cT1N0M0 OSCC
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Huashan Hospital
See details and how to joinNCT06623266 - Phase 2Taking peopleClinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma
- Where
- Shanghai
- Age
- 18 years and over
- People
- 140
- Run by
- HitGen Inc.
See details and how to joinNCT06781567 - Phase 3Not yet taking people in ChinaNeoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 300
- Run by
- caohaotian
See details and how to joinNCT07827872 - Phase 2Taking peopleNeoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC
- Where
- Chengdu
- Age
- 18 years and over
- People
- 9
- Run by
- West China Hospital
See details and how to joinNCT07572864